Study Provides Insights on Treatment and Prognosis of Male Breast Cancer

**Release Date:**
Monday, October 7, 2019 12:01 am EDT

**Terms:**
Cancer All Journals and Research Health Sciences

**Dateline City:**
Hoboken, NJ

**Contacts:**
Penny Smith +44 (0) 1243 770448 (UK) newsroom@wiley.com

A recent analysis published in *Cancer* reveals that treatment of male breast cancer has evolved over the years.

A recent analysis reveals that treatment of male breast cancer has evolved over the years. In addition, certain patient-, tumor-, and treatment-related factors are linked with better survival. The findings are published early online in *Cancer*, a peer-reviewed journal of the American Cancer Society.

Male breast cancer (MBC) comprises one percent of all breast cancer cases, yet no prospective randomized clinical trials specifically focused on MBC have been successfully completed. Some studies suggest that the incidence of MBC may be rising, however, and there is an increasing appreciation that the tumor biology of MBC differs from that of female breast cancer.

To examine how MBC has been treated in the United States in recent years, and to identify factors associated with patient prognosis, a team led by Kathryn Ruddy, MD, MPH, and Siddhartha Yadav, MBBS, at Mayo Clinic in Rochester, analyzed information from the National Cancer Database on men diagnosed with stage I-III breast cancer between 2004 and 2014.

A total of 10,873 patients with MBC were included, with a median age at diagnosis of 64 years. Breast-conserving surgery was performed in 24 percent of patients, and 70 percent of patients undergoing breast conservation received radiation. Forty-four percent of patients received chemotherapy, and 62 percent of patients whose tumors expressed the estrogen receptor received anti-estrogen therapy. During the study period, there was a significant increase in the rates of total mastectomy, contralateral prophylactic mastectomy, and post-breast conservation radiation, as well as an increase in the rate of genomic testing on tumors and the use of anti-estrogen therapy. Tamoxifen is the standard anti-estrogen medication recommended for treatment of hormonally sensitive MBC, but this study was not able to assess specific medications used.

Factors associated with worse overall survival were older age, black race, multiple comorbidities, high tumor grade and stage, and undergoing total mastectomy. Residing in higher income areas; having tumors that express the progesterone receptor; and receiving chemotherapy, radiation, and anti-estrogen therapy were associated with better overall survival.

“Our study highlights unique practice patterns and factors associated with prognosis in MBC, furthering our understanding of the treatment and prognosis of MBC,” said Dr. Ruddy. “The racial, economic, and age-related health disparities we found could inform future efforts to target interventions to optimize outcomes in men with breast cancer.”

October is Breast Cancer Awareness Month.

**Additional Information**

**NOTE:** The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the Cancer News Room upon online publication. For more information or to obtain a PDF of any study, please contact: Penny Smith +44 (0) 1243 770448 (UK) newsroom@wiley.com

Follow us on Twitter @WileyNews

**Full Citations:**

**URL Upon Publication:** http://doi.wiley.com/10.1002/cncr.32472

**Author Contact:** Joe Dangor, of the Mayo Clinic Public Affairs Office, at dangor.yusuf@mayo.edu.
About the Journal

*CANCER* is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of *CANCER* is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. *CANCER* is published on behalf of the American Cancer Society by Wiley and can be accessed online.


About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company’s website can be accessed at [www.wiley.com](http://www.wiley.com).

Language: English